News
Novo Nordisk, Maker of Obesity Drug Wegovy
Digest more
Denmark's economy remains robust despite job cuts at Novo Nordisk , the finance minister told Reuters on Wednesday, ...
It's no secret that Novo Nordisk ( NVO -1.69%) and Eli Lilly ( LLY 1.57%) are toughing it out in the battle of the weight ...
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
Novo Nordisk is deeply undervalued despite stellar fundamentals: 18% sales growth, a 29% OP jump, and a rock-solid balance ...
Novo Nordisk’s popular weight loss drug, Wegovy, is the first and only GLP-1 medication approved to treat metabolic associated steatohepatitis, a serious condition marked by liver scarring. The FDA ...
A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...
Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback